Should I Buy ACB? ACB 2026 Analysis

Should You Buy Aurora Cannabis Inc (ACB) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

3.480

1 Day change

5.14%

52 Week Range

6.910

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: price action and momentum are bearish (downtrend + weakening MACD), and the next-day/week statistical pattern also skews negative.
You’re heading into an earnings catalyst (pre-market 2026-02-04) with elevated implied volatility; that typically means a bigger move is priced in, but direction is unclear—bad odds for an impatient “buy now” approach.
If you want exposure anyway, the only “tactical” edge is that price is sitting just above near-term support (~3.97), but trend signals still argue against chasing.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend: Bearish structure with SMA_200 > SMA_20 > SMA_5 (clear downtrend across timeframes).
Momentum: MACD histogram -0.0144 (below zero) and negatively expanding → downside momentum is strengthening.
RSI (6): 39.25 → weak/soft momentum (not oversold enough to signal a strong bounce).
Key levels: Pivot 4.198 is overhead resistance; price (4.02) is below pivot.
- Support: S1 3.967 then S2 3.824 (break of 3.97 risks a quick push toward ~3.82).
- Resistance: R1 4.429 then R2 4.572 (would need a reversal to reclaim).
Pattern-based forecast (similar candlesticks): 70% chance of -1.33% next day, -4.62% next week, -4.5% next month → bearish bias.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment: Put/call ratios below 1 (OI 0.65, volume 0.63) lean bullish/less fear—calls outweigh puts.
Activity: Today’s option volume 715 vs 30D average (52.15%) → lighter-than-normal trading; sentiment signal isn’t strongly confirmed by heavy volume.
Volatility: 30D IV 79.2 vs historical vol 59.57 → options are pricing in large moves (especially relevant into earnings).
Positioning: Total OI 68,117 with call OI 41,348 vs put OI 26,769 → call-heavy open interest but not necessarily directional for the immediate post-earnings move.

Technical Summary

Sell

Buy

Positive Catalysts

- Earnings (QDEC 2025, reported 2026-02-04 pre-market): any upside surprise on revenue, margins, or guidance could trigger a sharp rebound given high IV.
- Canaccord initiation (2026-01-27): Buy rating with C$10 target; highlights strength in medical cannabis and higher-margin international markets.
- Europe push: launch of localized websites for key European markets reinforces long-term commitment and could support international channel growth/brand credibility.

Neutral/Negative Catalysts

- Technicals remain bearish (downtrend + worsening MACD); price is below pivot resistance and close to breaking S1 (~3.97).
- Earnings risk: expected EPS around -C$0.09 (loss expected), and the setup is “event-risky” with high IV—bad for an impatient entry.
- Latest reported profitability quality issue: gross margin in 2026/Q2 was negative (-8.86), a major deterioration YoY, raising concerns about cost structure/one-offs.
- No supportive flow signals: hedge funds and insiders are neutral; no notable accumulation trend.
- No recent congress trading data to suggest influential buying interest.

Financial Performance

Latest quarter provided: 2026/Q2.
Revenue: 90.37M, +11.40% YoY → steady top-line growth.
Net income: -51.47M (loss), improved vs prior year (reported as +319.14% YoY improvement) → losses narrowing, but still meaningfully negative.
EPS: -0.91, improved YoY (+313.64%), but still a loss.
Gross margin: -8.86, down sharply YoY (-968.63%) → major red flag on underlying profitability/production mix or one-time impacts.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent change: 2026-01-27 Canaccord initiated coverage at Buy with a C$10 price target.
Pros (Wall St view): “Medical-first” positioning and international exposure (Germany/Poland/Australia/UK) where margins are cited as materially higher.
Cons (Wall St risk lens): despite the bullish initiation, the company still shows weak/unstable profitability (notably negative gross margin) and the stock is trading in a clear technical downtrend—execution and margin normalization remain the key debate.

1 Analyst Rating

Wall Street analysts forecast ACB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACB is 4.32 USD with a low forecast of 4.32 USD and a high forecast of 4.32 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

1 Hold

0 Sell

Hold

Current: 3.310

Low

4.32

Averages

4.32

High

4.32

Current: 3.310

Low

4.32

Averages

4.32

High

4.32

Canaccord

Buy

downgrade

$10 -> $9

AI Analysis

2026-02-05

New

Reason

Canaccord

Price Target

$10 -> $9

AI Analysis

2026-02-05

New

downgrade

Buy

Reason

Canaccord lowered the firm's price target on Aurora Cannabis to C$9 from C$10 and keeps a Buy rating on the shares.

Canaccord

Buy

initiated

$10

2026-01-27

Reason

Canaccord

Price Target

$10

2026-01-27

initiated

Buy

Reason

Canaccord initiated coverage of Aurora Cannabis with a Buy rating and C$10 price target. The medical-first operator is "the leading medical player" in Canada and "a foremost player" in the key international markets of Germany, Poland, Australia, and the UK, the analyst tells investors in a note starting coverage of the the Canadian cannabis group. A domestic pivot supported an expansion into the high-margin international markets, where gross margins are roughly 2.5-times higher, on average, than in Aurora's medically focused Canadian business, the analyst noted.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ACB

Unlock Now

ACB Should I Buy

ACB Should I Buy

Should You Buy Aurora Cannabis Inc (ACB) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch